Green Valley is a Chinese pharmaceutical company with the courage to face up to toughest human health challenges with a high sense of responsibility. We are also known for innovative R&D within the Chinese pharmaceutical industry. We develop only the medicine that human beings most hope for, and bring about meaningful changes to people’s life.
We are deep diving into the gut-brain axis study with a holistic view of treatment. Based on these findings, we are possible to uncover a new angle to interpret the pathogenesis of chronic and complex diseases. Those insights are expected to become a major driving force to help us address unmet medical needs.
We exist for the patients worldwide who are suffering from chronic and complex diseases.
Currently, the human disease spectrum is undergoing tremendous changes, and factors affecting human health have gone far beyond gene or cell. Only by means of returning to the very origin essence of life can we discover the fundamental solutions. For chronic and complex diseases including neuroscience, oncology, cardiovascular, metabolism and autoimmunity, a single-target treatment strategy is inadequate to meet medical needs.. As a result, tens of thousands of patients affected are still in a predicament where there's no treatment for their diseases. Thus, we focus our efforts on carbohydrate drugs development to seek better choices for patients worldwide.
Neuropsychiatric diseases, oncology, cardiovascular diseases, metabolic diseases and autoimmune diseases
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. was founded.
GV-971 was approved conditionally by NMPA on November.
GV-971 officially launched the Chinese market on December.
Green Valley officially kicked off construction on its carbohydrate drug manufacturing facility in Shanghai on July, which will be the first manufacturing site in China that supplies carbohydrate drugs globally.
GV-971 received approval by FDA on the IND application for a global multi-center Phase III clinical trial on April and kicked off patient-enrollment process on October.
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. was authorized with pharmaceutical manufacturing license.
GV-971 Gets Included in China National Reimbursement Drug List.